Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has announced that it is collaborating with Muriel Zohar, the CEO of Life Sources Partners Ltd. The collaboration has been formed with the intention to propel the personalized and palliative cannabinoid cancer care. The company also announced that the State of Israel has granted it the Notice of Allowance. The Patent office has granted the company patent for its high throughput method of screening cancer cells.
The patent covers the technology that is essential for producing data and establishing interaction between the cancer cells and different cannabinoids. With this high throughput screening, it is possible to test the effects of various compounds that are extracted from the marijuana plant. The screening test is performed on biopsies and cancer cell lines.
Cannabics trying to bring cannabinoids into mainstream medicine
According to the the chief technology officer, and co-founder of Cannabics, Dr. Eyal Ballan, “Our aim is to build the intellectual property necessary to personalize cannabinoid diagnostics and treatment for cancer patients.” said Dr. Eyal Ballan, Cannabics co-founder and chief technology officer.
He further added that the company is currently compiling data that will demonstrate the effectiveness of cannabinoids in treating the cancer symptoms and also that it is effective in fighting cancer. Ballan thinks that this patent can be considered as a major leap in the field of technology that will bring the underutilized cannabinoids into the mainstream fraternity of medicine. The company is known for leading the cannabinoid diagnostic tests used for personalized cancer treatment.
Dr. Zohar looking forward to supporting Cannabics team
As a part of the collaboration, Dr. Zohar will first asses new opportunities for the project and then offer his strategic business insight so that the company continues to lead in the field of cannabinoid diagnostics and therapeutic applications and expand rapidly. Dr. Zohar said that he is looking forward to being a part of the cannabics team and support it.
Just a few days ago, the company made an announcement that the senior members from its scientific team will be present at the International Cannabinoid Research Society conference to be held between July 1 and July 4, 2018, in Leiden, Netherland.
Horizon ETFs Management Launches Two new ETFs At the Back of The Green Bond ETF Launch
Horizon ETFs Management Inc. has announced the launch of two new ETFs, including Horizons Global Hydrogen Index ETF (HYDR) and Horizons Global Lithium Producers Index ETF (HLIT). The ETFs’ units commenced trading on the Toronto Stock Exchange immediately under ticker TSX: HYDR and TSX: HLIT, respectively.
HDRY and HLIT first ETFs of their kind
Each ETF is the first of its nature in the respective segment, with HYDR being the first-hydrogen-leaning ETF in Canada while HLIT will be the first lithium ETF in the country. The two new ETF’s plus the Horizons Global Uranium Index ETF now form Horizon ETFs’ collection of alternative energy funds providing exposure to future-focused, non-conventional energy components, and sources.
HLIT will replicate the performance of an index providing exposure of publicly traded companies engaging in lithium production, lithium compounds, and lithium-related components. On the other hand, HYDR will replicate the performance of indexes offering exposure to the performance of globally listed companies dealing with fuel cell technology.
Demand for green bonds is high.
Horizon ETFs CEO Steve Hawkins said that the demand for ESG ETFs had been increasing. The company recently launched the first green bond ETF in Canada, Horizons S&P Green Bond Index ETF, an ESG ETF with massive potential. The ETF offers exposure to clean transportation, renewable energy, and pollution clean-up, which are exciting fields. Hawkins said that more green bonds are being issued.
Horizon ETF announces share consolidation of certain ETFs
Recently the company announced share consolidation of certain ETFs and share splits of certain ETFs. The company consolidated BetaPro Silver- 2x Daily Bear ETF, BetaPro Crude Oil Inverse Leveraged Daily Bear ETF, and BetaPro S&P/TSX capped Energy- 2X daily Bear ETF.
Eve & Co Inc (OTCMKTS: EEVVF) Posts A Growth Of 430% In Cannabis Sales To Wholesale And Adult-Use Markets In 2021
Eve & Co Inc (OTCMKTS: EEVVF) reported cannabis revenues of $2.47 (up 430% YoY) in 2021.
The company recognized higher revenues from the sale of cannabis to the wholesale and adult-use markets.
Ships additional cannabis to customers in Germany
Eve & Co also shipped an additional quantity of EU GMP-certified cannabis to its customers in Germany in Q1 2021.
The company completed the shipment of cannabis products on February 11, 2021, to New Brunswick. Its products are available for online purchase and through retailers.
Eve & Co also completed the first shipment of Cannabis products on April 28, 2021, to Alberta. Privately owned retailers in the province can buy recreational cannabis products online.
Natural MedCo Ltd transports CIBB (cannabis-infused bath bombs)
Natural MedCo Ltd, an auxiliary of Eve & Co, completed the first shipment of cannabis-infused bath bombs called ‘The Optimist CBD Bath Bomb’ to the retailers based in Saskatchewan, Labrador, and Newfoundland.
Eve & Co released the fourth CIBB (cannabis-infused bath bomb) product in its cannabis 2.0 line. The company manufactured this product using nourishing and high-quality ingredients, CBD isolate, and blended with eucalyptus and natural peppermint oils. The Optimist CBD Bath Bomb is free from THC and possesses aromatic and terpene properties. It relaxes the mind and nourishes your body.
Eve & Co’s CEO, Melinda Rombouts, is pleased to unveil this product. The company added this new product to its bath bombs line, which is widely sold across the nation.
Melinda is excited that its bath bombs are performing well at the Ontario Cannabis Store. The company is optimistic its new CBD product would become a best seller.
Eve & Co’s dried flower products (28 g) are available in Indica and Sativa Blends. These products comprise sun-grown, hand-dried, hand-finished, machine trimmed cannabis flower to maintain high quality and optimal flavor.
Melinda is pleased to expand its distribution network nationwide. In addition, Eve brand plans to embrace the licensed retailers’ network in the Alberta market to boost its growth.
Eve & Co holds processing and cultivation licenses in Canada to sell and manufacture cannabis products such as cannabis plants, cannabis, and cannabis oil extraction.
Medicine Man Technologies Inc (OTCMKTS: SHWZ) Inks A Deal To Take Over Southern Colorado Growers: Reports A Robust Growth Of 504% YoY In Q1 2021 Revenues
Medicine Man Technologies Inc (OTCMKTS: SHWZ) signed an agreement to take over Southern Colorado Growers assets based in Huerfano County, Colorado, for $11.4 million.
The company will pay cash of $5.9 million when closing the acquisition and the balance of $5.4 million in its stock.
Medicine Man expects to close the deal in Q3 2021, subject to the receipt of local licensing and MED approval.
Produces biomass for PurpleBee’s extraction
The assets of Southern Colorado include hoop house cultivation facility/ equipment, 34 acres of land, greenhouse, and outdoor cultivation facility. With this purchase, Medicine Man enters cultivation to manufacture and supply high-quality cannabis to its Star Buds dispensaries. It will also manufacture biomass to support its PurpleBee’s production and extraction facility.
Plans to build more hoop house facilities
It is part of the significant expansions undertook by the Medicine Man and expects to construct more hoop house facilities in the coming quarters. Medicine Man manufactures high-quality flower comprising 30 strains. The company also bagged several Connoisseur Cup accolades for its select strains in the previous year.
Provides wholesale distillate
PurpleBee’s is a prominent provider of wholesale distillate to satisfy the demand in the CPG market. It also supplies high-quality distillate to the leading concentrates, vaporizers, and edibles companies.
Medicine Man’s CEO, Justin Dye, said the purchase is just the beginning of its foray into the cannabis space. He further said a deal with a premier cannabis cultivator like Southern Colorado allows it to provide premium quality flower to its customers in all of its 17 Star Buds locations in Colorado.
Justin said the acquisition of Southern Colorado also improves its capability dramatically to manufacture biomass on a large scale to feed its Purplebee’s MIP. Therefore, the entire cannabis industry in the state will benefit from its efforts. In addition, the takeover of Southern Colorado will improve its margins.
Medicine Man posted revenues of $19.3 million up (504% YoY) in Q1 2021. Its adjusted EBITDA is $5.8 million in Q1 2021. It holds a positive cash flow of $1.7 million from its operations in Q1 2021 compared to the loss of $2.5 million in the same period last year.
Justin is excited about Q1 2021 revenues. The growth is on the backdrop of implementing an operating system that showed an improvement in critical areas.